Founded in 2015, Qilu Puget Sound Biotherapeutic Corp. (d.b.a. Sound Biologics) is a privately held clinical stage biotechnology company in the greater Seattle area dedicated to developing next-generation antibody therapeutics.
Our proprietary MabPair™ technology enables the production of two distinct monoclonal antibodies from a single cell line, combining the power of combination therapy with the simplicity of a single drug product. MabPair™ offers advantages in flexibility, manufacturability, and cost efficiency over bispecific or conventional antibody combinations.
Our team of experienced scientists brings expertise in antibody engineering, cancer biology, immunology, neurobiology, and CMC development. Together, we advance innovative therapies for cancer, autoimmune, and neurodegenerative diseases.
